摘要
目的:探讨表柔比星新辅助化疗联合腔镜下保乳术治疗Ⅱ、Ⅲ期乳腺癌的临床疗效与安全性.方法:选取2014年1月—2015年1月我院收治的96例Ⅱ、Ⅲ期乳腺癌患者作为研究对象.按随机数字表法分为对照组与试验组,各48例.所有患者均接受表柔比星联合环磷酰胺与多西他赛新辅助化疗方案,对照组接受传统乳腺癌保乳术,试验组接受腔镜下的乳腺癌保乳术治疗,比较两组治疗效果及3年预后情况.结果:两组手术用时、术中淋巴结清扫数量比较,差异无统计学意义(P>0.05);试验组平均引流量少于对照组,拔管时间短于对照组,差异有统计学意义(P<0.05);两组有效率、3年生存率、远处转移率比较,差异无统计学意义(P>0.05);试验组中位无进展生存期长于对照组,局部复发率低于对照组,差异有统计学意义(P<0.05);两组治疗后并发症均为Ⅰ~Ⅱ级程度,经对症治疗或停药后缓解、消失.结论:表柔比星新辅助化疗联合腔镜下乳腺癌保乳术治疗Ⅱ、Ⅲ期乳腺癌的临床疗效理想且安全性较高,能够有效降低手术医源性损伤及术后局部复发率,具有临床应用及推广价值.
Objective:To investigate the clinical efficacy and safety of epirubicin neoadjuvant chemotherapy combined with laparoscopic breast-conserving surgery the treatment ofⅡandⅢstages of breast cancer.Methods:96 patients withⅡandⅢstages of breast cancer admitted to our hospital from January 2014 to January 2015 were selected as subjects investigated.The patients were randomly divided into a control group and an experimental group,48 cases each.All patients received neoadjuvant chemotherapy with epirubicin combined with CTX and docetaxel.The patients in the control group received conventional breast-conserving surgery for breast cancer,and the patients in the experimental group received laparoscopic breast-conserving surgery for breast cancer.Results:There were no statistically significant differences in surgical time and intraoperative lymph node dissections between the two groups(P>0.05).The average drainage volume in the experimental group was less than that in the control group,and the extubation time was shorter than that in the control group,with statistically significant differences(P<0.05).There were no statistically significant differences in the effective rate,3-year survival rate and distant metastasis rate between the two groups(P>0.05).The median progression-free survival time in the experimental group was longer than that in the control group,and the local recurrence rate was lower than that in the control group,with statistically significant differences(P<0.05).The complications after treatment in the two groups wereⅠstage toⅡstage,which were relieved and disappeared after symptomatic treatment or drug withdrawal.Conclusion:Epirubicin neoadjuvant chemotherapy combined with laparoscopic breast-conserving surgery has an ideal clinical therapeutic effect and high safety in the treatment ofⅡandⅢstages of breast cancer,which can effectively reduce iatrogenic injury and local recurrence rate after operation,and has clinical application and popularization value.
作者
范振宇
范艳冰
Fan Zhen-yu;Fan Yan-bing(Department of Surgery,Luohe Third People’s Hospital,Luohe Henan 462000,China)
出处
《中国合理用药探索》
CAS
2019年第6期138-141,共4页
Chinese Journal of Rational Drug Use
关键词
表柔比星
新辅助化疗
腔镜下乳腺癌保乳术
Ⅱ、Ⅲ期乳腺癌
临床疗效
预后结局
Epirubicin
Neoadjuvant Chemotherapy
Laparoscopic Breast-conserving Surgery for Breast Cancer
Ⅱ,ⅢStage Breast Cancer
Clinical Efficacy
Prognosis Outcome
